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Abstract
Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit
immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-
mediate escape leading to the development of a clinically overt cancer. In the recent years, clinical trials
demonstrating the efficacy of blocking antibodies against these molecules have invigorated the field of
immunotherapy. In this review, we discuss the current understanding on established NCR blockade and how
strategic combination therapy with anti-VISTA antibody can be used to target multiple non-redundant NCR
pathways.
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Background
Negative checkpoint regulator (NCR) blockade has begun
to establish itself as a cornerstone to multi-modality can-
cer treatment. Pioneered by seminal findings in multiple
mouse models and human cancers, monoclonal antibody
blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4)
has paved the way for the field of NCRs leading to discov-
ery of new molecules as well as uncovering novel
approaches for combination therapy targeting multiple
non-redundant pathways. In this review, we describe the
prevailing wisdom of mechanisms of action for established
NCR blockade. Further, we discuss the role of V-domain
Ig Suppressor of T Cell Activation (VISTA), a novel target
in immuno-oncology. Alongside the phase 1 clinical trial
testing anti-VISTA (NCT02671955), it becomes increas-
ingly important to have a comprehensive understanding
of how targeting VISTA advantageously shapes the tumor
microenvironment.
Blockade of CTLA-4 paving the way for checkpoint blockade
CTLA-4 is exclusively expressed on T cells, although not
on naïve or memory T cells. CTLA-4 has two binding
partners, B7 molecules CD80 and CD86, both of which
are expressed on antigen presenting cells (APCs).
CTLA-4 exerts its immunosuppression of T cell re-
sponses by multiple mechanisms. First, CTLA-4 out-
competes the co-stimulatory molecule CD28 for their
shared binding partners CD80 and CD86 as a result of
increased affinity, increased avidity, and more stable in-
teractions within the immunological synapse [1–6]. In
addition, upon disrupting co-simulation by CD28 and
ligation with cognate B7 molecules, CTLA-4 recruits the
inhibitory tyrosine phosphatase SHP-2 to the T cell re-
ceptor, thus attenuating the signal [1, 2, 7], destabilizing
the immunological synapse [1, 8], arresting cell cycling
[9], and reducing the production of IL-2 [1, 2, 7, 9].
CTLA-4 can also signal bi-directionally to induce the
upregulation of indoleamine 2,3-dioxygenase (IDO) by
APCs [10, 11]. In vivo, it is hypothesized that the pre-
dominant mechanism through which CTLA-4 downre-
gulates T cell response is via transcytosis of CD80 and
CD86 from the membranes of APCs, thus making these
molecules unavailable for co-stimulation by CD28 [1, 8,
12]. Furthermore, natural FoxP3+ regulatory T cells
(nTreg) constitutively express high levels of CTLA-4 on
their surface and both CTLA-4 on nTregs as well as
conventional T cells contribute to T cell immunosup-
pression [13].
The major role CTLA-4 plays in restraining T cell re-
sponses to maintain tolerance is evident in mice that
have a complete deficiency of CTLA-4 [1, 9, 14, 15].
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Within a few weeks, CTLA-4-/- mice die from
massive, spontaneous, lethal autoimmunity due to
unchecked lymphoproliferation [14, 15]. Activated T
cells aggressively infiltrated spleen and lymph nodes
as well as the liver, heart, lung and pancreas with
high immunoglobulin detected in the blood [14, 15].
This severe and widespread autoimmune phenotype
suggests that CTLA-4 primarily functions to control T cell
responses for maintaining immune homeostasis. Import-
antly, the absence of CTLA-4 specifically on Tregs is suffi-
cient for the development of autoimmunity, further
reiterating the major role of CTLA-4 in Treg mediated
suppression [16].
These observations that CTLA-4 functions to re-
strain T cell response led to the hypothesis that
blockade of CTLA-4 may lead to persistent T cell ac-
tivity within tumors. Success in multiple pre-clinical
models [17, 18], led to the development of Ipilimu-
mab (Bristol-Myers Squibb), a fully human IgG1
monoclonal antibody and first in class of NCR block-
ade. After two transformative phase III trials in mel-
anoma [19, 20], Ipilimumab received FDA approval in
2011 for the treatment of advanced melanoma. Fur-
ther, durable immunity was established evident by re-
sponses lasting up to 10 years in some patients [21].
The mechanisms underpinning the in vivo efficacy of
CTLA-4 blockade remains controversial. Targeting
both effector T cells and Tregs appear critical for
maximal anti-tumor activity [22]. However, anti-
CTLA-4 activity has also been linked to Fc mediated
Treg depletion at the tumor site by tumor infiltrating
macrophages [23, 24].
Blockade of PD-1/PD-L1 axis expanding boundaries
Similar to CTLA-4, Programmed cell death 1 (PD-1) is
not expressed on naïve or memory T cells but is
expressed on activated and exhausted T cells [25, 26].
PD-1 has two binding partners, Programmed cell death
ligand 1 (PD-L1) and Programmed cell death ligand 2
(PD-L2). Though the role of PD-L2 as a target in
immuno-oncology has yet to be clarified [27, 28], ample
pre-clinical and clinical data demonstrate the relevance
of PD-L1. PD-L1 is expressed on dendritic cells, macro-
phages, myeloid-derived suppressor cells (MDSCs), fi-
broblasts, and T cells [28–30]. PD-L1 has also been
detected in multiple human cancer cells including breast
cancer, colon cancer, glioblastoma, non-small cell lung
cancer, melanoma, and ovarian cancers, among others
[29]. In addition, some tumors such as melanoma ex-
press PD-1 which can directly promote tumorigenesis in
a cell-intrinsic fashion by modulating mTOR pathways.
Therefore, anti-PD-1 antibodies can also directly inhibit
tumor growth [31].
Unlike CTLA-4, PD-1/PD-L1 engagement does not
interfere with co-stimulation but negatively regulates
anti-tumor immunity through apoptosis and inhib-
ition of T cell signaling. Tumor cell expression of
PD-L1 ligation triggers apoptosis of activated T cells
leading to the loss of T cells in vivo and subsequent
outgrowth of tumor [32–34]. Ligation of PD-L1 and
PD-1 negatively regulates T cell activity by multiple
ways. The cytoplasmic domain of PD-1 includes a
conventional immunoreceptor tyrosine-based inhib-
ition motif (ITIM) and immunoreceptor tyrosine-
based switch motif (ITSM) which bind inhibitory
tyrosine phosphatase SHP-2 [33], disrupts TCR-
induced stop signal [35], and promotes T cell motil-
ity to limit the time of cognate interactions [36].
In contrast to CTLA-4 -/- mice, PD-L1-/- [32] and PD-
1 -/- [37, 38] mice do not develop massive, lethal
lymphoproliferative disease. Instead, there is only organ-
specific inflammation further supporting the fact that
CTLA-4 and PD-1 function at different stages of im-
mune activation.
The prior success of anti-CTLA-4 led to accelerated
development of antibodies targeting PD-1 [39, 40]
and PD-L1 [41]. Studies testing these new drugs un-
covered several distinctions from anti-CTLA-4 ther-
apy. In addition to enhanced efficacy in melanoma
[39–41], disrupting the PD-1 pathway demonstrated
efficacy in non small cell lung cancer [39, 41, 42],
which was previously thought to be refractory to im-
munotherapy. Second, treatment with drugs blocking
PD-1/PD-L1 caused fewer immune related adverse
events than anti-CTLA-4, which is consistent with
the less severe inflammatory phenotype of PD-1 and
PD-L1 deficient mice compared to that of CTLA-4
deficient mice. Several drugs targeting either PD-1
(Nivolumab, Bristol-Myers Squibb; Pembrolizumab,
Merck) or PD-L1 (Atezolizumab, Roche) have re-
ceived accelerated FDA approval for various applica-
tions and more are in development.
Maximizing response with combination therapy
Though a subset of patients responds to NCR block-
ade as monotherapy, the majority of patients do not
respond to the release of a single axis. Thus, combin-
ation therapy targeting multiple pathways may provide
additional support to the development of anti-tumor
host immunity. Indeed, combination of drugs target-
ing CTLA-4 or the PD-1/PD-L1 pathway led to syn-
ergistic efficacy versus monotherapy in both murine
models and patients [43–45] leading to FDA approval
of combination Ipilimumab and Nivolumab for ad-
vanced melanoma.
Synergist clinical activity with combination therapy
indicate non-redundant mechanisms of action for
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anti-CTLA-4 and anti-PD-1, which may be attributed
to differential regulatory mechanisms dictating target
expression. Expression of CTLA-4 is induced by TCR
signaling [9] and surface expression is rapidly upregu-
lated by mobilizing large intracellular pools of CTLA-
4. Combined with the observation that its ligands
CD80 and CD86 are expressed on APCs, it is believed
that the CTLA-4 axis works to restrain T cells within
secondary lymphoid organs where T cell activation oc-
curs [1, 19, 20]. In contrast to CTLA-4, it is viewed
that PD-1/PD-L1 pathway acts to restrain T cell re-
sponses in the peripheral tissues, such as at the tumor
bed where ligand and receptor are both in abundance
[1, 34, 46, 47]. PD-L1 can be upregulated by tumor
cell oncogenes [48–53] or by other mediators highly
expressed within the tumor microenvironment (TME)
such as tumor hypoxia [30], TLR-mediated signaling
pathways [54], and IFNγ [55]. As a result, future stud-
ies identifying regulatory mechanisms governing NCR
expression may help guide strategic combination ther-
apy and also aid in selecting patients to optimize treat-
ment protocol.
Another approach to improving the response to
NCR blockade, is reversing mechanisms which limit
its efficacy. There are multiple mediators which sub-
vert the full potential of immunotherapy such as
tumor-infiltrating MDSCs. MDSCs are a group of
heterogeneous, immature myeloid cells that are ag-
gressively expanded and pathologically activated by
tumor-derived factors [56]. MDSCs exert suppression
over T cells through multiple mechanisms including
the production of reactive oxygen species, nitric
oxide, and arginase [57]; ultimately leading to T cell
suppression [58] and increased tumor burden [57].
Importantly, the accumulation of MDSCs within the
tumor bed has emerged as an important mechanism
of resistance to immunotherapy such as NCR block-
ade. In combination anti-PD-1 and anti-CTLA-4 in
B16 melanoma, reduced treatment efficacy was ob-
served when MDSCs were recruited via IDO overex-
pression (B16-IDO) by the tumor [59, 60] and
blocking MDSCs recruitment via CSF-1R blockade
improved efficacy in B16-IDO but not in B16. In
CT26 colon carcinoma model, characterized by its ag-
gressive MDSC compartment [61], MDSC depletion
enhanced the efficacy of the combination therapy of
anti-CTLA-4 and anti-PD-1. While late intervention
of anti-PD-1 and anti-CTLA-4 on large, established
CT26 colon cancer and 4 T1 breast cancer did not
have any therapeutic efficacy, supplementing the com-
bination therapy with 5-azacytidine and etinostat to
inhibit MDSCs, sensitized tumors to NCR blockade
leading to tumor reduction [62]. Together, these stud-
ies clearly demonstrate that targeting MDSCs as part
of NCR blockade may provide an additional dimen-
sion to therapeutic efficacy.
VISTA: a new horizon in NCR blockade
VISTA, also known as c10orf54, PD-1H [63, 64], DD1α
[65], Gi24 [66], Dies1 [67], and SISP1 [68] is a member
of the B7 family of NCRs and represents a new target
for immunotherapy. Murine VISTA is a type I trans-
membrane protein with a single IgV domain with se-
quence homology to its B7 relatives with conserved
segments thought to be critical for the IgV stability [69].
However, VISTA also has unique features such as add-
itional cysteine residues in the Ig-V domain, an insertion
of a long loop between the C” and D strands, and the
absence of a second Ig domain in the ectodomain [69].
These features suggest that VISTA could function as a
receptor as well as a ligand. Indeed, structural modeling
suggest homology to either PD-1 [63] or PD-L1 [69].
However, VISTA does not cluster with the B7 family at
standard confidence limits, suggesting that it is only
weakly associated with this family [69]. VISTA is the
most conserved among the B7 members. Human VISTA
shares 78% identity with murine VISTA according to a
Global Alignment Search Tool, an unprecedented se-
quence identity among NCRs. By comparison, human
and murine PD-L1, PD-L2, CTLA-4 and PD-1 share
70%, 63%, 76%, and 59% sequence identity, respectively.
In particular, the cytoplasmic tail of VISTA is highly
conserved in mice and humans with 86.5% identity and
VISTA’s unique features in the extracellular domain are
also highly conserved.
The surface expression pattern of VISTA is clearly
distinct from CTLA-4, PD-1, and PD-L1. [1] VISTA is
expressed on naïve T cells [69] whereas PD-1 and
CTLA-4 are not, which may suggest that VISTA func-
tions to restrain T cell activity at an even earlier stage
in T cell priming. [2] VISTA is expressed on both T
cells and APCs with very high expression on myeloid
cells [69]. [3] VISTA is hematopoietically restricted
and in multiple cancer models, VISTA was only de-
tected on tumor infiltrating leukocytes and not on
tumor cells [70]. This unique surface expression pat-
tern suggests that VISTA may function to restrict T
cell immunity at different stages compared to PD-1/
PD-L1 and CTLA-4 axes. Importantly, the pattern of
VISTA expression is remarkably similar between hu-
man and mice (Table 1). Interestingly, VISTA is abun-
dantly stored within intracellular compartments
(unpublished), similar to CTLA-4. In fact, the intracel-
lular CTLA-4 compartment is a key component in the
stringent regulation of surface CTLA-4. Intracellular
CTLA-4 is mobilized to the surface following T cell
stimulation in a magnitude which is directly propor-
tional to TCR signaling [5, 71–73]. Comparably, the
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majority of VISTA is detected within the intracellular
compartment of myeloid cells with surface VISTA rap-
idly endocytosed (unpublished). However, steady, but
high, levels of VISTA are maintained on the cellular
surface of myeloid cells [69, 70, 74]. Studies investigat-
ing the mechanisms underlying intracellular and sur-
face VISTA expression are ongoing.
VISTA has been demonstrated to exert both ligand
and receptor functions. First, VISTA can function as a
ligand to negatively regulate T cell activation. In vitro,
VISTA on APCs and cell-free VISTA-Ig fusion protein
(extracellular domain of VISTA fused with human
IgG1 Fc) inhibited CD8+ and CD4+ T cell at the early
stage of activation indicated by suppression of CD69,
CD25, CD44, and CD62L [69]. VISTA Ig suppressed
the production of IL-2 and IFNγ in both CD4+ naïve
and memory T cells as well as in CD8+ T cells [69].
Unlike the PD-1/PD-L1 pathway, VISTA does not dir-
ectly regulate T cell response by the induction of
apoptosis [69]. VISTA-Ig fusion protein also promotes
in vitro conversion of naïve CD4+ T cells to Tregs in
both mouse and human [74, 75]. VISTA expression
on Tregs also contributes to the suppression of T cell
proliferation in in vitro suppression assay [70]. Finally,
in mice that were vaccinated with irradiated MCA105
tumor cells to generate immunity, re-challenge with
VISTA-overexpressing MCA105 tumor cells lead en-
hanced tumor growth compared to re-challenge with
the VISTA negative parent MCA105 indicating that
VISTA expression can overcome protective anti-
tumor immunity [69].
Second, VISTA has been demonstrated to function
as a receptor on T cells which negatively regulates
their activity. VISTA-/- CD4+ T cells respond more
vigorously than wild type (WT) CD4+ T cells to both
polyclonal and antigen specific stimulation leading to
increased proliferation and production of IFNγ, TNFα,
and IL-17A [64]. In addition, VISTA-/- T cells induce
exacerbated graft-versus-host disease (GVHD) com-
pared to WT T cells when transferred into F1 recipi-
ents [76]. When WT CD4+ T cells are stimulated in
vitro or in vivo in the absence of VISTA on APCs, an
anti-VISTA agonist antibody (mam82), which can only
target VISTA on the T cell, reduces antigen specific
activation [64]. Finally, another anti-VISTA agonist
antibody (MH5A) prevents the development of
GVHD induced by WT T cells [63] but is ineffective
when disease is induced by VISTA -/- T cells [76]. In
addition to T cells, VISTA can also function as a re-
ceptor on myeloid cells. Transfection of monocytes
from healthy donors to overexpress VISTA led to the
spontaneous secretion of inflammatory cytokines IL-8,
IL-1β, IL-6, TNFα, and IL-10 [77]. In HIV positive
patients, infected monocytes expressed higher
amounts of VISTA than healthy monocytes and also
spontaneously expressed more TNFα, IL-1β, and IL6
mRNA than healthy monocytes did [77]. VISTA
transfected HIV-infected monocytes induced enhanced
IFNγ production by antigen-specific autologous T
cells compared to vector control and silenced VISTA
[77]. In this transfection system with HIV infected
monocytes, VISTA-mediated myeloid activation and
subsequent T cell activation overshadowed VISTA-
driven immunosuppressive functions. VISTA highly
conserved cytoplasmic tail does not contain any clas-
sic signaling motif. However, it contains potential pro-
tein kinase C binding sites as well as proline residues
that could function as docking sites for adaptor pro-
teins. In addition, it contains multiple potential serine,
threonine, and tyrosine phosphorylation sites. Import-
antly, the transfection of monocyte with cytoplasmic
tail-deficient VISTA abrogated the spontaneous elab-
oration of cytokine [77], suggesting that signaling
through VISTA is both possible and required. The ap-
parent opposing functions of VISTA T cells and
monocytes is unresolved and requires further investi-
gation. One possible explanation for this discrepancy
is the dysregulated level of VISTA expression in
transfected or HIV infected monocytes. Other nega-
tive checkpoints inhibitors have been associated with
positively or negatively regulating innate cells activity
depending on their expression level [78].
In multiple mouse models, VISTA expression is up-
regulated in the TME and plays a critical role in
shaping anti-tumor immunity [70]. Distinct from PD-
L1, VISTA expression is restricted to the tumor-
infiltrating leukocytes and was not detected on tumor
cells. In particular, VISTA expression is specifically
upregulated on tumor infiltrating myeloid cells such
as myeloid DCs and MDSCs, and on tumor
Table 1 VISTA expression levels on human and murine subsets
as evaluated by FACS analysis
Cell Type Surface VISTA expression
Human Mouse
CD4+ naïve T cells + ++
CD4+ FoxP3+ Treg + ++
CD4+ memory T cells + ++
CD8+ T cells + +
B cells - -
NK cells - -
Peritoneal macrophages N/D +++
Monocytes +++ +++
Neutrophils +++ +++
Dendritic cells +++ +++
Adapted from Wang et al. and Lines et al
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infiltrating Tregs compared to those in the periphery
[70]. On MDSCs, VISTA increased almost 10-fold on
tumor-infiltrating leukocytes compared to those found
in the peripheral lymph node [70]. Importantly, this
indicates that tumors with infiltrating immune cells
and especially MDSCs may harbor abundant levels of
VISTA available for therapeutic targeting.
Anti-VISTA monotherapy reduced tumor growth in
multiple pre-clinical models, B16OVA melanoma, B16-
BL6 melanoma, MB49 bladder carcinoma, and PTEN/
BRAF inducible melanoma [70]. In all models, anti-
VISTA enhanced T cell response within the TME as well
as systemically leading to increased accumulation, prolif-
eration, CD44 expression, and IFNγ and TNFα produc-
tion [70]. Additionally, VISTA blockade reduced natural
Treg mediated suppression of T cells and diminished
tumor-induced differentiation of Tregs [70]. Finally,
anti-VISTA reduced tumor-infiltrating MDSCs in the
B16OVA and PTEN/BRAF melanoma models [70]. Since
abnormal myelopoiesis and accumulation of MDSCs are
characteristic of many tumors [79], normalizing the
myeloid component offers a new opportunity for immu-
nomodulation by anti-VISTA, a mechanism distinct
from other forms of NCR blockade. An anti-human
VISTA antibody is currently in phase I clinical trial for
evaluation in patients with non-small cell lung cancer
among other cancers. The mouse surrogate of anti-
human VISTA antibody demonstrated tumor growth in-
hibition by modulating of the myelomonocytic and T cell
compartments in human VISTA knock-in mice [80].
Important to its clinical potential as a therapeutic tar-
get, some aspect of VISTA mediated regulation are
unique and therefore, targeting VISTA synergizes with
the mechanism of actions of the NCRs currently
targeted in the clinic (Fig. 1). Combination antibody
blockade (anti-VISTA and anti-PD-1 or anti-PD-L1) syn-
ergistically enhanced T cell responses [81]. Ultimately,
combination therapy led to reduced tumor growth, en-
hanced survival, increased IFNγ, tumor necrosis factor
(TNFα), and Granzyme B within CD8+ T cells further
supporting a mechanism of action non-redundant to
established NCR blockade in clinic.
Conclusion
Identification of NCRs as critical mechanisms limiting T
cell response and the use of monoclonal antibody block-
ade to support the development of persistent T cell im-
munity in the setting of cancer have transformed cancer
therapy. Lessons learned from anti-CTLA-4 and anti-
PD-1 pathway blockade have encouraged continued
discovery and development of NCR blockade while re-
vealing additional opportunities for improvement. As
combination immunotherapy continues to rise to the
forefront of cancer treatment, targeting VISTA may offer
a particularly attractive and unique opportunity for syn-
ergism due to its role in restricting very early T cell acti-
vation events and high expression on tumor infiltrating
MDSCs suggesting that anti-VISTA pathway blockade
may occupy a distinct therapeutic compartment.
Fig. 1 VISTA functions non-redundantly to NCRs currently targeted in clinic. Each NCR occupies distinct temporal and spatial opportunities for
blockade to release T cell suppression: [1] VISTA, as a receptor on T cells inhibit early T cell activation while [2] CTLA-4/CD80-86 interaction inhibit
post-TCR signaling in secondary lymphoid organs. [3] PD-1/PD-L1 interaction inhibits effector T cells in inflamed tumor tissue. [4] VISTA, as a
ligand on MDSCs engages counter structure to inhibit T cells in tumor tissue and secondary lymphoid organs
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